Skip to main
RAPP
RAPP logo

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has experienced a notable increase in share momentum following its inaugural R&D Day and the positive Phase 2a data released on September 8, indicating strong investor interest and confidence in the company's prospects. The preclinical and Phase 1 high-voltage studies support the recent first-in-patient Phase 2a results in treating refractory focal onset epilepsy (FOS) with RAP-219, which demonstrates a significantly improved therapeutic window. Given the rapid and substantial seizure control observed with RAP-219, even a slight reduction in efficacy is predicted to lead to successful Phase 3 trial outcomes, potentially positioning the drug with a competitive commercial profile in the market.

Bears say

Rapport Therapeutics Inc faces significant challenges that underpin a negative outlook for its stock, primarily related to the efficacy results of its Phase 2a trials, which may not accurately predict outcomes in Phase 3 due to potential overestimation stemming from trial design flaws. Additionally, the commercial prospects for its treatments could be adversely affected by strong competition in the market and the prospect of unfavorable insurance coverage, which may limit access for patients. The overall risk of diminished efficacy and potential market barriers raises concerns about the company's ability to successfully monetize its therapeutic candidates, impacting its financial viability.

RAPP has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 3 analysts, RAPP has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.